Project Grant R18EB037603
- This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health (NIH), provides $3,473,616 to the University of Connecticut to develop a novel implantable neuromodulation system called "SmartStim" to treat chronic pain. The goal is to create a combined device and drug treatment that can selectively block sensitized nociceptive (pain-sensing) nerve fibers, especially C-fibers, to reverse the underlying neural...
- The Project Grant award of $675,107 from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program, supports research to develop novel non-opioid, non-addictive analgesics for treating neuropathic pain. The project, led by Northeastern University, will focus on designing and evaluating "dualsteric modulators" that act as both cannabinoid CB1 receptor...
- This Project Grant award for $668,131 was provided by the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), under the Drug Use and Addiction Research Programs (CFDA 93.279). The purpose of the award is to conduct research on chronic neuropathic pain (CNP) and understand how alterations in dopamine function and reward processing may contribute to the affective symptoms of CNP. The research aims to quantify changes in dopamine release in the nucleus...
- This $1,563,778 Project Grant was awarded by the National Institute of Neurological Disorders and Stroke under the NIH's Drug Use and Addiction Research Programs (CFDA 93.279) on September 12, 2024. The grant supports research conducted by Duke University to develop equilibrative nucleoside transporter (ENT1) inhibitors as potential non-opioid pain therapeutics. The project aims to: 1) validate ENT1 as a novel target for neuropathic pain treatment, 2) characterize a novel ENT1 inhibitor compound...
- This $173,799 federal Project Grant was awarded by the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), under the Drug Use and Addiction Research Programs (CFDA 93.279). The grant was awarded on May 1, 2025 to The Trustees of the University of Pennsylvania, doing business as the Clinical Practices of the University of Pennsylvania, to support research aimed at revealing, at the cellular and neural circuit levels, how the endogenous opioid system is...
- This $416,250.00 Project Grant award from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), under the "Discovery and Applied Research for Technological Innovations to Improve Human Health" federal grant program (CFDA 93.286), supports research and development of novel in situ formed microneedle-like depots for spatiotemporally controlled drug delivery. The goal is to create a new drug delivery strategy based on intralesional printing of drug-eluting biomaterial...
- This federal Project Grant award, provided by the National Institute of Neurological Disorders and Stroke (NINDS) under the Drug Use and Addiction Research Programs (CFDA 93.279), is focused on developing novel methods for selectively stimulating nociceptors (pain receptors) and measuring the brain's nociceptive-specific response in both healthy individuals and those with the chronic pain condition fibromyalgia. The $2,314,276 award to Emory University will fund the creation of a new...
- This $2,370,000 federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to develop advanced human pluripotent stem cell (HPSC) tools to create comprehensive, region-specific models for studying pain circuitry. The award to Trustees of Tufts College (Tufts University) supports three main objectives: 1) Developing scalable methods to generate region-specific sensory neurons and...
- This federal Project Grant award in the amount of $5,057,591 was provided by the National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health (NIH), under the Drug Use and Addiction Research Programs (CFDA 93.279). The purpose of the award is to conduct a comprehensive, prospective observational study with 2,400 emergency department patients seeking care for acute pain. The study aims to: 1) characterize clinically-informed pain phenotypes, 2)...
- This Cooperative Agreement award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $2,932,500.00 in funding to The Drug Delivery Company, LLC to develop a bioabsorbable, subcutaneous, extended-release buprenorphine implant for the treatment of opioid use disorder. The project aims to build upon the company's successful development of a 6-month bioabsorbable naltrexone implant, known as ISTEP-N, which demonstrated the...
This $2,668,301 Project Grant was awarded by the National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health (NIH), under the Drug Use and Addiction Research Programs (CFDA 93.279). The grant funds the development of an implantable, biodegradable drug delivery device for localized, long-duration administration of non-opioid pain medications after surgery. The University of Connecticut will synthesize protein-based film materials conjugated with polymers to control the release of the local anesthetic ropivacaine. The research aims to characterize the drug release properties of the materials in vitro and then assess the safety and efficacy of the implantable films. This project has the potential to transform post-operative pain management by providing a localized, long-acting alternative to opioid-based treatments.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $2.7m | 9/15/25 |